Tsuchimoto Kim R.'s most recent trade in Monopar Therapeutics Inc was a trade of 2,055 Common Stock done at an average price of $30 . Disclosure was reported to the exchange on Aug. 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 26 Aug 2026 | 2,055 | 2,055 (0%) | 0% | 30 | 61,650 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2026 | 2,055 | 6,165 | - | - | Stock Option | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2026 | 2,035 | 8,140 | - | - | Stock Option | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 26 Aug 2026 | 2,035 | 4,090 (0%) | 0% | 14 | 28,490 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 111.84 per share. | 26 Aug 2026 | 1,098 | 8,588 (0%) | 0% | 111.8 | 122,800 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 111.84 per share. | 26 Aug 2026 | 1,098 | 1,192 (0%) | 0% | 111.8 | 122,800 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 110.65 per share. | 26 Aug 2026 | 700 | 9,686 (0%) | 0% | 110.7 | 77,455 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 110.65 per share. | 26 Aug 2026 | 700 | 2,290 (0%) | 0% | 110.7 | 77,455 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 109.56 per share. | 26 Aug 2026 | 615 | 10,386 (0%) | 0% | 109.6 | 67,379 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 109.56 per share. | 26 Aug 2026 | 615 | 2,990 (0%) | 0% | 109.6 | 67,379 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 112.93 per share. | 26 Aug 2026 | 602 | 7,986 (0%) | 0% | 112.9 | 67,984 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 112.93 per share. | 26 Aug 2026 | 602 | 590 (0%) | 0% | 112.9 | 67,984 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 113.84 per share. | 26 Aug 2026 | 590 | 7,396 (0%) | 0% | 113.8 | 67,166 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 113.84 per share. | 26 Aug 2026 | 590 | 0 (0%) | 0% | 113.8 | 67,166 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 108.83 per share. | 26 Aug 2026 | 485 | 11,001 (0%) | 0% | 108.8 | 52,783 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 108.83 per share. | 26 Aug 2026 | 485 | 3,605 (0%) | 0% | 108.8 | 52,783 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2025 | 2,924 | 2,924 | - | - | Stock Options | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | 14 Jul 2025 | 8,904 | 20,390 (0%) | 0% | 0.0 | 45 | Common Stock | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 14 Jul 2025 | 8,904 | 11,486 (0%) | 0% | 40.0 | 356,171 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | 14 Jul 2025 | 4,704 | 0 | - | - | Stock Options | ||
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | 14 Jul 2025 | 4,200 | 0 | - | - | Stock Options | ||
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 11,365 | 11,365 | - | - | Stock Options | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2024 | 9,957 | 60,427 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2024 | 9,957 | 74,412 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.73 per share. | 30 Jun 2024 | 2,998 | 57,429 (0%) | 0% | 0.7 | 2,192 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 9,956 | 84,369 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 9,956 | 54,552 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.68 per share. | 31 Mar 2024 | 4,082 | 50,470 (0%) | 0% | 0.7 | 2,780 | Common Stock |
| Monopar Therapeutics Inc | R. Kim Tsuchimoto | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 9,957 | 95,556 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | R. Tsuchimoto Kim | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 9,957 | 47,943 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Tsuchimoto R. Kim | Director, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 31 Dec 2023 | 4,073 | 43,870 (0%) | 0% | 0.3 | 1,386 | Common Stock |
| Monopar Therapeutics Inc | Kim Tsuchimoto R. | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 1,231 | 94,325 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Tsuchimoto Kim R. | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 1,231 | 45,101 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Tsuchimoto Kim R. | Director, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 31 Dec 2023 | 505 | 44,596 (0%) | 0% | 0.3 | 172 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 14,846 | 115,469 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 14,846 | 36,578 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.86 per share. | 30 Jun 2023 | 5,104 | 31,474 (0%) | 0% | 0.9 | 4,364 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 5,067 | 23,574 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 5,067 | 130,315 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Director, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.39 per share. | 31 Mar 2023 | 1,842 | 21,732 (0%) | 0% | 1.4 | 2,560 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 102,688 | 102,688 | - | - | Stock Options | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 78,234 | 135,382 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 5,067 | 19,846 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 5,067 | 55,917 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 31 Dec 2022 | 2,067 | 17,779 (0%) | 0% | 2.4 | 4,899 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 1,230 | 1,231 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 1,230 | 19,009 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 31 Dec 2022 | 502 | 18,507 (0%) | 0% | 2.4 | 1,190 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 5,066 | 16,532 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 5,066 | 63,445 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.52 per share. | 30 Sep 2022 | 1,753 | 14,779 (0%) | 0% | 1.5 | 2,665 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 8,913 | 68,511 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 8,913 | 14,549 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.30 per share. | 30 Jun 2022 | 3,083 | 11,466 (0%) | 0% | 2.3 | 7,088 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 1,221 | 6,136 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 1,221 | 77,424 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.55 per share. | 31 Mar 2022 | 500 | 5,636 (0%) | 0% | 2.6 | 1,275 | Common Stock |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 1,231 | 5,420 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 1,231 | 2,461 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Kim R. Tsuchimoto | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.21 per share. | 01 Jan 2022 | 505 | 4,915 (0%) | 0% | 3.2 | 1,621 | Common Stock |